

Targeted therapy in low-grade glioma

see [Targeted therapy for pediatric low-grade glioma](#)

Liu Z, Cheng X, Pang B, Wang S, Liu B, Cao C, Qian R, Liang W, Zhu Y, Li P, Gao Y. Effects of [ESCO2](#) or its methylation on the prognosis, clinical characteristics, immune microenvironment, and pathogenesis of [low-grade glioma](#). *Int Immunopharmacol*. 2022 Jan 7;104:108399. doi: 10.1016/j.intimp.2021.108399. Epub ahead of print. PMID: 35008004.

2: Liu Z, Ren Z, Zhang C, Qian R, Wang H, Wang J, Zhang W, Liu B, Lian X, Wang Y, Guo Y, Gao Y. [ELK3](#): A New Molecular Marker for the Diagnosis and Prognosis of Glioma. *Front Oncol*. 2021 Dec 16;11:608748. doi: 10.3389/fonc.2021.608748. PMID: 34976781; PMCID: PMC8716454.

3: Howden K, Chapman S, Serletis D, Kazina C, Rafay MF, Faury D, Hazrati LN, Jabado N, Vanan MI. Management of Inoperable Supra-Sellar Low-Grade Glioma With BRAF Mutation in Young Children. *Cureus*. 2021 Nov 9;13(11):e19400. doi: 10.7759/cureus.19400. PMID: 34926002; PMCID: PMC8656291.

4: Noor H, Zaman A, Teo C, Sughrue ME. [PODNL1](#) Methylation Serves as a Prognostic Biomarker and Associates with Immune Cell Infiltration and Immune Checkpoint Blockade Response in Lower-Grade Glioma. *Int J Mol Sci*. 2021 Nov 22;22(22):12572. doi: 10.3390/ijms222212572. PMID: 34830454; PMCID: PMC8625785.

5: Chen R, Wang X, Dai Z, Wang Z, Wu W, Hu Z, Zhang X, Liu Z, Zhang H, Cheng Q. [TNFSF13](#) Is a Novel Onco-Inflammatory Marker and Correlates With Immune Infiltration in Gliomas. *Front Immunol*. 2021 Oct 12;12:713757. doi: 10.3389/fimmu.2021.713757. PMID: 34712225; PMCID: PMC8546343.

6: Zimu Z, Jia Z, Xian F, Rui M, Yuting R, Yuan W, Tianhong W, Mian M, Yinlong L, Enfang S. Decreased Expression of [PACSL1](#) in Brain Glioma Samples Predicts Poor Prognosis. *Front Mol Biosci*. 2021 Aug 5;8:696072. doi: 10.3389/fmolb.2021.696072. PMID: 34422904; PMCID: PMC8375027.

7: Lin Z, Wen M, Yu E, Lin X, Wang H, Chen J, Yao C, Zhang H, Ru J, Wang K, Zhang Y, Huang L, Zhuge Q, Yang S. [ANXA1](#) as a Prognostic and Immune Microenvironmental Marker for Gliomas Based on Transcriptomic Analysis and Experimental Validation. *Front Cell Dev Biol*. 2021 Aug 4;9:659080. doi: 10.3389/fcell.2021.659080. PMID: 34422796; PMCID: PMC8371204.

8: Vlachos N, Lampros MG, Zigouris A, Voulgaris S, Alexiou GA. Anaplastic gangliogliomas of the spinal cord: a scoping review of the literature. *Neurosurg Rev*. 2021 Jul 27. doi: 10.1007/s10143-021-01612-3. Epub ahead of print. PMID: 34312775.

9: Wang Z, Chen X, Liang Q, An Y, Wei M, Shi W. Inhibiting of circ-TLK1 inhibits the progression of glioma through down-regulating PANX1 via targeting miR-17-5p. *J Mol Histol*. 2021 Oct;52(5):1007-1020. doi: 10.1007/s10735-021-09993-x. Epub 2021 Jun 28. PMID: 34181173.

10: Deng T, Gong Y, Liao X, Wang X, Zhou X, Zhu G, Mo L. Integrative Analysis of a Novel Eleven-Small Nucleolar RNA Prognostic Signature in Patients With Lower Grade Glioma. *Front Oncol*. 2021 Jun 7;11:650828. doi: 10.3389/fonc.2021.650828. PMID: 34164339; PMCID: PMC8215672.

11: Sarma S, Khonglah Y, Mishra J, Kakati A, Phukan P. Gliomas - An experience based on molecular

markers. *J Family Med Prim Care*. 2021 Mar;10(3):1341-1346. doi: 10.4103/jfmpc.jfmpc_1963_20. Epub 2021 Apr 8. PMID: 34041176; PMCID: PMC8140246.

12: Jiang Y, Wang Z, Ying C, Hu J, Zeng T, Gao L. FMR1/circCHAF1A/miR-211-5p/HOXC8 feedback loop regulates proliferation and tumorigenesis via MDM2-dependent p53 signaling in GSCs. *Oncogene*. 2021 Jun;40(24):4094-4110. doi: 10.1038/s41388-021-01833-2. Epub 2021 May 20. PMID: 34017077.

13: Jünger ST, Timmermann B, Pietsch T. Pediatric ependymoma: an overview of a complex disease. *Childs Nerv Syst*. 2021 Aug;37(8):2451-2463. doi: 10.1007/s00381-021-05207-7. Epub 2021 May 18. PMID: 34008056; PMCID: PMC8342354.

14: Zhu Z, Zhang X, Yu Z, Zhou Y, Zhu S, Zhang YH, Lin XP, Mou Y, Zhang J. Correlation of Tim-3 expression with chemokine levels for predicting the prognosis of patients with glioblastoma. *J Neuroimmunol*. 2021 Jun 15;355:577575. doi: 10.1016/j.jneuroim.2021.577575. Epub 2021 Apr 20. PMID: 33901809.

15: Peeters SM, Muftuoglu Y, Na B, Daniels DJ, Wang AC. Pediatric Gliomas: Molecular Landscape and Emerging Targets. *Neurosurg Clin N Am*. 2021 Apr;32(2):181-190. doi: 10.1016/j.nec.2020.12.001. Epub 2021 Feb 18. PMID: 33781501.

16: Yang J, Yang Q. Identification of Core Genes and Screening of Potential Targets in Glioblastoma Multiforme by Integrated Bioinformatic Analysis. *Front Oncol*. 2021 Feb 24;10:615976. doi: 10.3389/fonc.2020.615976. PMID: 33718116; PMCID: PMC7943725.

17: Li X, Meng Y. Expression and prognostic characteristics of m⁵C regulators in low-grade glioma. *J Cell Mol Med*. 2021 Feb;25(3):1383-1393. doi: 10.1111/jcmm.16221. Epub 2021 Jan 5. PMID: 33400376; PMCID: PMC7875931.

18: Qi Y, Liu B, Sun Q, Xiong X, Chen Q. Immune Checkpoint Targeted Therapy in Glioma: Status and Hopes. *Front Immunol*. 2020 Nov 27;11:578877. doi: 10.3389/fimmu.2020.578877. PMID: 33329549; PMCID: PMC7729019.

19: Lombardi G, Barresi V, Castellano A, Tabouret E, Pasqualetti F, Salvalaggio A, Cerretti G, Caccese M, Padovan M, Zagonel V, Ius T. Clinical Management of Diffuse Low-Grade Gliomas. *Cancers (Basel)*. 2020 Oct 16;12(10):3008. doi: 10.3390/cancers12103008. PMID: 33081358; PMCID: PMC7603014.

20: Wang J, Zhang Y, You A, Li J, Gu J, Rao G, Ge X, Zhang K, Fu H, Liu X, Li J, Wang Q, Wu X, Cheng L, Zhu M, Wang D. HAS2-AS1 Acts as a Molecular Sponge for miR-137 and Promotes the Invasion and Migration of Glioma Cells by Targeting EZH2. *Cell Cycle*. 2020 Nov;19(21):2826-2835. doi: 10.1080/15384101.2020.1826237. Epub 2020 Oct 16. PMID: 33064966; PMCID: PMC7714441.

21: Szalontay L, Khakoo Y. Medulloblastoma: an Old Diagnosis with New Promises. *Curr Oncol Rep*. 2020 Jul 9;22(9):90. doi: 10.1007/s11912-020-00953-4. PMID: 32643099.

22: Miklja Z, Yadav VN, Cartaxo RT, Siada R, Thomas CC, Cummings JR, Mullan B, Stallard S, Paul A, Bruzek AK, Wierzbicki K, Yang T, Garcia T, Wolfe I, Leonard M, Robertson PL, Garton HJ, Wahl DR, Parmar H, Sarkaria JN, Kline C, Mueller S, Nicolaidis T, Glasser C, Leary SE, Venneti S, Kumar-Sinha C, Chinnaiyan AM, Mody R, Pai MP, Phoenix TN, Marini BL, Koschmann C. Everolimus improves the efficacy of dasatinib in PDGFR α -driven glioma. *J Clin Invest*. 2020 Oct 1;130(10):5313-5325. doi: 10.1172/JCI133310. PMID: 32603316; PMCID: PMC7524471.

23: Ma Q, Wang X, Wang H, Song W, Wang Q, Wang J. HMGN5 Silencing Suppresses Cell Biological

Progression via AKT/MAPK Pathway in Human Glioblastoma Cells. *Biomed Res Int*. 2020 May 21;2020:8610271. doi: 10.1155/2020/8610271. PMID: 32596388; PMCID: PMC7273445.

24: Young JS, Gogos AJ, Morshed RA, Hervey-Jumper SL, Berger MS. Molecular characteristics of diffuse lower grade gliomas: what neurosurgeons need to know. *Acta Neurochir (Wien)*. 2020 Aug;162(8):1929-1939. doi: 10.1007/s00701-020-04426-2. Epub 2020 May 30. PMID: 32472378.

25: Collins KL, Pollack IF. Pediatric Low-Grade Gliomas. *Cancers (Basel)*. 2020 May 4;12(5):1152. doi: 10.3390/cancers12051152. PMID: 32375301; PMCID: PMC7281318.

26: Wang Y, Zhao B, Chen W, Liu L, Chen W, Zhou L, Kong Z, Dai C, Wang Y, Ma W. Pretreatment Geriatric Assessments of Elderly Patients with Glioma: Development and Implications. *Aging Dis*. 2020 Mar 9;11(2):448-461. doi: 10.14336/AD.2019.0527. PMID: 32257553; PMCID: PMC7069455.

27: Cooney T, Yeo KK, Kline C, Prados M, Haas-Kogan D, Chi S, Mueller S. Neuro- Oncology Practice Clinical Debate: targeted therapy vs conventional chemotherapy in pediatric low-grade glioma. *Neurooncol Pract*. 2020 Jan;7(1):4-10. doi: 10.1093/nop/npz033. Epub 2019 Aug 13. PMID: 32257279; PMCID: PMC7104878.

28: Packer RJ, Iavarone A, Jones DTW, Blakeley JO, Bouffet E, Fisher MJ, Hwang E, Hawkins C, Kilburn L, MacDonald T, Pfister SM, Rood B, Rodriguez FJ, Tabori U, Ramaswamy V, Zhu Y, Fangusaro J, Johnston SA, Gutmann DH. Implications of new understandings of gliomas in children and adults with NF1: report of a consensus conference. *Neuro Oncol*. 2020 Jun 9;22(6):773-784. doi: 10.1093/neuonc/noaa036. PMID: 32055852; PMCID: PMC7283027.

29: Tabibkhooei A, Izadpanahi M, Arab A, Zare-Mirzaei A, Minaeian S, Rostami A, Mohsenian A. Profiling of novel circulating microRNAs as a non-invasive biomarker in diagnosis and follow-up of high and low-grade gliomas. *Clin Neurol Neurosurg*. 2020 Mar;190:105652. doi: 10.1016/j.clineuro.2019.105652. Epub 2019 Dec 27. PMID: 31896490.

30: Liu QJ, Lv JX, Liu J, Zhang XB, Wang LB. Nucleobindin-2 Promotes the Growth and Invasion of Glioblastoma. *Cancer Biother Radiopharm*. 2019 Nov;34(9):581-588. doi: 10.1089/cbr.2019.2829. PMID: 31697592.

31: Chen W, Lei C, Liu P, Liu Y, Guo X, Kong Z, Wang Y, Dai C, Wang Y, Ma W, Wang Y. Progress and Prospects of Recurrent Glioma: A Recent Scientometric Analysis of the Web of Science in 2019. *World Neurosurg*. 2020 Feb;134:e387-e399. doi: 10.1016/j.wneu.2019.10.078. Epub 2019 Oct 19. PMID: 31639500.

32: Laviv Y. [DIFFUSE Low-grade glioma: PERSONALIZED ADAPTATION OF SURGICAL RESECTION IN AN ERA OF TARGETED ONCOLOGICAL THERAPY]. *Harefuah*. 2019 Sep;158(9):601-606. Hebrew. PMID: 31507113.

33: Yin Y, Li B, Mou K, Khan MT, Kaushik AC, Wei D, Zhang YJ. Stoichioproteomics reveal oxygen usage bias, key proteins and pathways in glioma. *BMC Med Genomics*. 2019 Aug 29;12(1):125. doi: 10.1186/s12920-019-0571-y. PMID: 31464612; PMCID: PMC6716898.

34: Otani Y, Ichikawa T, Kurozumi K, Date I. Dynamic Reorganization of Microtubule and Glioma Invasion. *Acta Med Okayama*. 2019 Aug;73(4):285-297. doi: 10.18926/AMO/56930. PMID: 31439951.

35: Tan MSY, Sandanaraj E, Chong YK, Lim SW, Koh LWH, Ng WH, Tan NS, Tan P, Ang BT, Tang C. A STAT3-based gene signature stratifies glioma patients for targeted therapy. *Nat Commun*. 2019 Aug 9;10(1):3601. doi: 10.1038/s41467-019-11614-x. PMID: 31399589; PMCID: PMC6689009.

- 36: Liu J, Liu D, Yang Z, Yang Z. High LAMC1 expression in glioma is associated with poor prognosis. *Onco Targets Ther*. 2019 May 29;12:4253-4260. doi: 10.2147/OTT.S205333. PMID: 31213842; PMCID: PMC6549796.
- 37: Park AK, Lee JY, Cheong H, Ramaswamy V, Park SH, Kool M, Phi JH, Choi SA, Cavalli F, Taylor MD, Kim SK. Subgroup-specific prognostic signaling and metabolic pathways in pediatric medulloblastoma. *BMC Cancer*. 2019 Jun 11;19(1):571. doi: 10.1186/s12885-019-5742-x. PMID: 31185958; PMCID: PMC6560914.
- 38: Erel-Akbaba G, Carvalho LA, Tian T, Zinter M, Akbaba H, Obeid PJ, Chiocca EA, Weissleder R, Kantarci AG, Tannous BA. Radiation-Induced Targeted Nanoparticle-Based Gene Delivery for Brain Tumor Therapy. *ACS Nano*. 2019 Apr 23;13(4):4028-4040. doi: 10.1021/acsnano.8b08177. Epub 2019 Mar 27. PMID: 30916923; PMCID: PMC7104714.
- 39: Wang X, Guo G, Guan H, Yu Y, Lu J, Yu J. Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma. *J Exp Clin Cancer Res*. 2019 Feb 18;38(1):87. doi: 10.1186/s13046-019-1085-3. PMID: 30777100; PMCID: PMC6380009.
- 40: Sala L, Cirillo G, Riva G, Romano G, Giussani C, Cialdella A, Todisco A, Virtuoso A, Cerrito MG, Bentivegna A, Grassilli E, Ardizzoia A, Bonoldi E, Giovannoni R, Papa M, Lavitrano M. Specific Expression of a New Bruton Tyrosine Kinase Isoform (p65BTK) in the Glioblastoma Gemistocytic Histotype. *Front Mol Neurosci*. 2019 Jan 24;12:2. doi: 10.3389/fnmol.2019.00002. PMID: 30733667; PMCID: PMC6353843.
- 41: Sarkiss CA, Germano IM. Machine Learning in Neuro-Oncology: Can Data Analysis from 5,346 Patients Change Decision Making Paradigms? *World Neurosurg*. 2019 Jan 23:S1878-8750(19)30141-X. doi: 10.1016/j.wneu.2019.01.046. Epub ahead of print. PMID: 30684706.
- 42: Chen CH, Chen PY, Lin YY, Feng LY, Chen SH, Chen CY, Huang YC, Huang CY, Jung SM, Chen LY, Wei KC. Suppression of tumor growth via IGFBP3 depletion as a potential treatment in glioma. *J Neurosurg*. 2019 Jan 11;132(1):168-179. doi: 10.3171/2018.8.JNS181217. PMID: 30641835.
- 43: D'Alessandris QG, Montano N, Martini M, Cenci T, Lauretti L, Stumpo V, Pignotti F, Olivi A, Fernandez E, Larocca LM, Pallini R. Eight-year survival of a Glioblastoma recurrence patient treated with molecularly tailored therapy: a case report. *Acta Neurochir (Wien)*. 2018 Dec;160(12):2387-2391. doi: 10.1007/s00701-018-3697-3. Epub 2018 Oct 11. PMID: 30306271.
- 44: Hashimoto Y, Penas-Prado M, Zhou S, Wei J, Khatua S, Hodges TR, Sanai N, Xiu J, Gatalica Z, Kim L, Kesari S, Rao G, Spetzler D, Heimberger A. Rethinking medulloblastoma from a targeted therapeutics perspective. *J Neurooncol*. 2018 Sep;139(3):713-720. doi: 10.1007/s11060-018-2917-2. Epub 2018 Jun 5. PMID: 29869738; PMCID: PMC6132970.
- 45: Miller KE, Kelly B, Fitch J, Ross N, Avenarius MR, Varga E, Koboldt DC, Boué DR, Magrini V, Coven SL, Finlay JL, Cottrell CE, White P, Gastier-Foster JM, Wilson RK, Leonard J, Mardis ER. Genome sequencing identifies somatic *BRAF* duplication c.1794_1796dupTAC;p.Thr599dup in pediatric patient with low-grade ganglioglioma. *Cold Spring Harb Mol Case Stud*. 2018 Apr 2;4(2):a002618. doi: 10.1101/mcs.a002618. PMID: 29434027; PMCID: PMC5880266.
- 46: Wagner LM, Myseros JS, Lukins DE, Willen CM, Packer RJ. Targeted therapy for infants with diencephalic syndrome: A case report and review of management strategies. *Pediatr Blood Cancer*. 2018 May;65(5):e26917. doi: 10.1002/pbc.26917. Epub 2018 Jan 25. PMID: 29369501.

- 47: Dong Y, Furuta T, Sabit H, Kitabayashi T, Jiapaer S, Kobayashi M, Ino Y, Todo T, Teng L, Hirao A, Zhao SG, Nakada M. Identification of antipsychotic drug fluspirilene as a potential anti-glioma stem cell drug. *Oncotarget*. 2017 Dec 4;8(67):111728-111741. doi: 10.18632/oncotarget.22904. PMID: 29340087; PMCID: PMC5762355.
- 48: Jones DTW, Kieran MW, Bouffet E, Alexandrescu S, Bandopadhyay P, Bornhorst M, Ellison D, Fangusaro J, Fisher MJ, Foreman N, Fouladi M, Hargrave D, Hawkins C, Jabado N, Massimino M, Mueller S, Perilongo G, Schouten van Meeteren AYN, Tabori U, Warren K, Waanders AJ, Walker D, Weiss W, Witt O, Wright K, Zhu Y, Bowers DC, Pfister SM, Packer RJ. Pediatric low-grade gliomas: next biologically driven steps. *Neuro Oncol*. 2018 Jan 22;20(2):160-173. doi: 10.1093/neuonc/nox141. Erratum in: *Neuro Oncol*. 2018 Jan 22;20(2):293. PMID: 29016845; PMCID: PMC5786244.
- 49: Zhu P, Zhu JJ. Tumor treating fields: a novel and effective therapy for glioblastoma: mechanism, efficacy, safety and future perspectives. *Chin Clin Oncol*. 2017 Aug;6(4):41. doi: 10.21037/cco.2017.06.29. PMID: 28841803.
- 50: Jain P, Fierst TM, Han HJ, Smith TE, Vakil A, Storm PB, Resnick AC, Waanders AJ. CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles. *Oncogene*. 2017 Nov 9;36(45):6348-6358. doi: 10.1038/onc.2017.276. Epub 2017 Aug 14. PMID: 28806393; PMCID: PMC5680138.
- 51: Furuta T, Sabit H, Dong Y, Miyashita K, Kinoshita M, Uchiyama N, Hayashi Y, Hayashi Y, Minamoto T, Nakada M. Biological basis and clinical study of glycogen synthase kinase- β -targeted therapy by drug repositioning for glioblastoma. *Oncotarget*. 2017 Apr 4;8(14):22811-22824. doi: 10.18632/oncotarget.15206. PMID: 28423558; PMCID: PMC5410264.
- 52: Pirozzi CJ, Carpenter AB, Waitkus MS, Wang CY, Zhu H, Hansen LJ, Chen LH, Greer PK, Feng J, Wang Y, Bock CB, Fan P, Spasojevic I, McLendon RE, Bigner DD, He Y, Yan H. Mutant IDH1 Disrupts the Mouse Subventricular Zone and Alters Brain Tumor Progression. *Mol Cancer Res*. 2017 May;15(5):507-520. doi: 10.1158/1541-7786.MCR-16-0485. Epub 2017 Feb 1. PMID: 28148827; PMCID: PMC5415422.
- 53: Zhou XW, Wang X, Yang Y, Luo JW, Dong H, Liu YH, Mao Q. Biomarkers related with seizure risk in glioma patients: A systematic review. *Clin Neurol Neurosurg*. 2016 Dec;151:113-119. doi: 10.1016/j.clineuro.2016.10.001. Epub 2016 Nov 2. PMID: 27821299.
- 54: Packer RJ, Pfister S, Bouffet E, Avery R, Bandopadhyay P, Bornhorst M, Bowers DC, Ellison D, Fangusaro J, Foreman N, Fouladi M, Gajjar A, Haas-Kogan D, Hawkins C, Ho CY, Hwang E, Jabado N, Kilburn LB, Lassaletta A, Ligon KL, Massimino M, Meeteren SV, Mueller S, Nicolaidis T, Perilongo G, Tabori U, Vezina G, Warren K, Witt O, Zhu Y, Jones DT, Kieran M. Pediatric low-grade gliomas: implications of the biologic era. *Neuro Oncol*. 2017 Jun 1;19(6):750-761. doi: 10.1093/neuonc/now209. PMID: 27683733; PMCID: PMC5464436.
- 55: Narayanappa R, Rout P, Aithal MG, Chand AK. Aberrant expression of Notch1, HES1, and DTX1 genes in glioblastoma formalin-fixed paraffin-embedded tissues. *Tumour Biol*. 2016 May;37(5):6935-42. doi: 10.1007/s13277-015-4592-7. Epub 2015 Dec 11. PMID: 26662803.
- 56: Sloan AE, Okada H, Ryken TC, Kalkanis SN, Olson JJ. The role of emerging therapy in the management of patients with diffuse Low-grade glioma. *J Neurooncol*. 2015 Dec;125(3):631-5. doi: 10.1007/s11060-015-1865-3. Epub 2015 Nov 3. PMID: 26530260.
- 57: Johnson J, Ascierto ML, Mittal S, Newsome D, Kang L, Briggs M, Tanner K, Marincola FM, Berens ME, Vande Woude GF, Xie Q. Genomic profiling of a Hepatocyte growth factor-dependent signature for

MET-targeted therapy in glioblastoma. *J Transl Med.* 2015 Sep 17;13:306. doi: 10.1186/s12967-015-0667-x. PMID: 26381735; PMCID: PMC4574608.

58: Qiu X, Ji B, Yang L, Huang Q, Shi W, Ding Z, He X, Ban N, Fan S, Zhang J, Tian Y. The role of FoxJ2 in the migration of human glioma cells. *Pathol Res Pract.* 2015 May;211(5):389-97. doi: 10.1016/j.prp.2015.01.005. Epub 2015 Jan 21. PMID: 25661068.

59: Demetriades AK, Almeida AC, Bhangoo RS, Barrington SF. Applications of positron emission tomography in neuro-oncology: a clinical approach. *Surgeon.* 2014 Jun;12(3):148-57. doi: 10.1016/j.surge.2013.12.001. Epub 2014 Mar 11. PMID: 24629841.

60: Griguer CE, Cantor AB, Fathallah-Shaykh HM, Gillespie GY, Gordon AS, Markert JM, Radovanovic I, Clement-Schatlo V, Shannon CN, Oliva CR. Prognostic relevance of cytochrome C oxidase in primary glioblastoma multiforme. *PLoS One.* 2013 Apr 10;8(4):e61035. doi: 10.1371/journal.pone.0061035. PMID: 23593382; PMCID: PMC3622606.

61: Huang H, Xiang Y, Su B, Xiong W, Zhang X. Potential roles for Gfi1 in the pathogenesis and proliferation of glioma. *Med Hypotheses.* 2013 May;80(5):629-32. doi: 10.1016/j.mehy.2013.02.007. Epub 2013 Mar 5. PMID: 23466061.

62: Xu T, Qin R, Zhou J, Yan Y, Lu Y, Zhang X, Fu D, Lv Z, Li W, Xia C, Hu G, Ding X, Chen J. High bone sialoprotein (BSP) expression correlates with increased tumor grade and predicts a poorer prognosis of high-grade glioma patients. *PLoS One.* 2012;7(10):e48415. doi: 10.1371/journal.pone.0048415. Epub 2012 Oct 31. PMID: 23119009; PMCID: PMC3485236.

63: Yan W, Zhang W, You G, Zhang J, Han L, Bao Z, Wang Y, Liu Y, Jiang C, Kang C, You Y, Jiang T. Molecular classification of gliomas based on whole genome gene expression: a systematic report of 225 samples from the Chinese Glioma Cooperative Group. *Neuro Oncol.* 2012 Dec;14(12):1432-40. doi: 10.1093/neuonc/nos263. Epub 2012 Oct 22. PMID: 23090983; PMCID: PMC3499016.

64: Zhang JJ, Weng RG, Liu J, Chen HP, Liu J, Ye H, Zheng WM. [Targeted therapy of malignant glioma by a chimeric fusion toxin composed of IL-13 and *Pseudomonas* exotoxin in vitro]. *Zhonghua Yi Xue Za Zhi.* 2012 Mar 20;92(11):731-4. Chinese. PMID: 22781350.

65: Larysz D, Kula D, Kowal M, Rudnik A, Jarząb M, Blamek S, Bierzyńska-Macyszyn G, Kowalska M, Bażowski P, Jarząb B. Epidermal growth factor receptor gene expression in High-grade gliomas. *Folia Neuropathol.* 2011;49(1):28-38. PMID: 21455841.

66: Karsy M, Albert L, Tobias ME, Murali R, Jhanwar-Uniyal M. All-trans retinoic acid modulates cancer stem cells of glioblastoma multiforme in an MAPK-dependent manner. *Anticancer Res.* 2010 Dec;30(12):4915-20. PMID: 21187470.

67: Wagemakers M, Sie M, Hoving EW, Molema G, de Bont ES, den Dunnen WF. Tumor vessel biology in pediatric intracranial ependymoma. *J Neurosurg Pediatr.* 2010 Apr;5(4):335-41. doi: 10.3171/2009.11.PEDS09260. PMID: 20367336.

68: Ye F, Gao Q, Cai MJ. Therapeutic targeting of EGFR in malignant gliomas. *Expert Opin Ther Targets.* 2010 Mar;14(3):303-16. doi: 10.1517/14728221003598948. PMID: 20148717.

69: Hargrave D. Paediatric high and Low-grade glioma: the impact of tumour biology on current and future therapy. *Br J Neurosurg.* 2009 Aug;23(4):351-63. doi: 10.1080/02688690903158809. PMID: 19637006.

70: Ohba S, Hirose Y, Yoshida K, Yazaki T, Kawase T. Inhibition of 90-kD heat shock protein potentiates the cytotoxicity of chemotherapeutic agents in human glioma cells. J Neurosurg. 2010 Jan;112(1):33-42. doi: 10.3171/2009.3.JNS081146. PMID: 19408974.

71: Sawamura Y, de Tribolet N. [Immunobiology](#) of brain tumors. Adv Tech Stand Neurosurg. 1990;17:3-64. doi: 10.1007/978-3-7091-6925-4_1. PMID: 2180410.

From:

<https://neurosurgerywiki.com/wiki/> - **Neurosurgery Wiki**

Permanent link:

https://neurosurgerywiki.com/wiki/doku.php?id=targeted_therapy_in_low-grade_glioma

Last update: **2024/06/07 02:56**

